collection
https://read.qxmd.com/read/32647324/covid-19-severity-and-mortality-in-patients-with-chronic-lymphocytic-leukemia-a-joint-study-by-eric-the-european-research-initiative-on-cll-and-cll-campus
#1
MULTICENTER STUDY
Lydia Scarfò, Thomas Chatzikonstantinou, Gian Matteo Rigolin, Giulia Quaresmini, Marina Motta, Candida Vitale, Jose Antonio Garcia-Marco, José Ángel Hernández-Rivas, Fatima Mirás, Mónica Baile, Juan Marquet, Carsten U Niemann, Gianluigi Reda, Talha Munir, Eva Gimeno, Monia Marchetti, Francesca Maria Quaglia, Marzia Varettoni, Julio Delgado, Sunil Iyengar, Ann Janssens, Roberto Marasca, Angela Ferrari, Carolina Cuéllar-García, Gilad Itchaki, Martin Špaček, Lorenzo De Paoli, Luca Laurenti, Mark-David Levin, Enrico Lista, Francesca R Mauro, Martin Šimkovič, Ellen Van Der Spek, Elisabeth Vandenberghe, Livio Trentin, Ewa Wasik-Szczepanek, Rosa Ruchlemer, Dominique Bron, Maria Rosaria De Paolis, Giovanni Del Poeta, Lucia Farina, Myriam Foglietta, Massimo Gentile, Yair Herishanu, Tobias Herold, Ozren Jaksic, Arnon P Kater, Sabina Kersting, Lara Malerba, Lorella Orsucci, Viola Maria Popov, Paolo Sportoletti, Mohamed Yassin, Barbara Pocali, Gabor Barna, Annalisa Chiarenza, Gimena Dos Santos, Eugene Nikitin, Martin Andres, Maria Dimou, Michael Doubek, Alicia Enrico, Yervand Hakobyan, Olga Kalashnikova, Macarena Ortiz Pareja, Maria Papaioannou, Davide Rossi, Nimish Shah, Amit Shrestha, Oana Stanca, Niki Stavroyianni, Vladimir Strugov, Constantine Tam, Mihnea Zdrenghea, Marta Coscia, Kostas Stamatopoulos, Giuseppe Rossi, Alessandro Rambaldi, Emili' Montserrat, Robin Foà, Antonio Cuneo, Paolo Ghia
Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission)...
September 2020: Leukemia
https://read.qxmd.com/read/30700842/infections-associated-with-immunotherapeutic-and-molecular-targeted-agents-in-hematology-and-oncology-a-position-paper-by-the-european-conference-on-infections-in-leukemia-ecil
#2
REVIEW
Georg Maschmeyer, Julien De Greef, Sibylle C Mellinghoff, Annamaria Nosari, Anne Thiebaut-Bertrand, Anne Bergeron, Tomas Franquet, Nicole M A Blijlevens, Johan A Maertens
A multitude of new agents for the treatment of hematologic malignancies has been introduced over the past decade. Hematologists, infectious disease specialists, stem cell transplant experts, pulmonologists and radiologists have met within the framework of the European Conference on Infections in Leukemia (ECIL) to provide a critical state-of-the-art on infectious complications associated with immunotherapeutic and molecular targeted agents used in clinical routine. For brentuximab vedotin, blinatumomab, CTLA4- and PD-1/PD-L1-inhibitors as well as for ibrutinib, idelalisib, HDAC inhibitors, mTOR inhibitors, ruxolitinib, and venetoclax, a detailed review of data available until August 2018 has been conducted, and specific recommendations for prophylaxis, diagnostic and differential diagnostic procedures as well as for clinical management have been developed...
April 2019: Leukemia
https://read.qxmd.com/read/30290904/passive-transfer-of-anti-hbc-after-intravenous-immunoglobulin-administration-in-patients-with-cancer-a-retrospective-chart-review
#3
JOURNAL ARTICLE
Huifang Lu, Anna S Lok, Carla L Warneke, Sairah Ahmed, Harrys A Torres, Fernando Martinez, Maria E Suarez-Almazor, Jessica T Foreman, Alessandra Ferrajoli, Jessica P Hwang
BACKGROUND: Patients previously infected with hepatitis B virus (HBV; indicated by positivity for anti-HBc) can experience HBV reactivation during cancer chemotherapy. Intravenous immunoglobulin infusion, which is frequently used in supportive care, might facilitate passive transfer of anti-HBc. We aimed to estimate the probability of passive transfer of anti-HBc after intravenous immunoglobulin infusion in patients with cancer. METHODS: We reviewed institutional databases to identify adult patients who received outpatient chemotherapy between Jan 1, 2004, and Dec 31, 2011, at the University of Texas MD Anderson Cancer Center, Houston, TX, USA...
October 2018: Lancet Haematology
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.